ELENCO STUDI CLINICI
Titolo: European, prospective, multicenter, non-interventional, non-comparative clinical registry to evaluate the clinical outcome and safety of the treatment of severely infected patients with IV fosfomycin.
Acronimo: FORTRESS
Disegno dello Studio: studio osservazionale, multicentrico, profit, senza farmaco
Promotore: InfectoPharm GmbH
Sperimentatore Principale in ISMETT: Dott.ssa Alessandra Mularoni
Titolo: A Phase 3/4, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Acronimo: MAESTRO_NASH
Disegno dello Studio: studio interventistico, multicentrico, profit, con farmaco
Promotore: Madrigal Pharmaceuticals
Sperimentatore Principale in ISMETT: Dott. Alessandro Mattina
Titolo: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD)
Acronimo: A4250
Disegno dello Studio: studio interventistico, multicentrico, profit, con farmaco
Promotore: Albireo
Sperimentatore Principale in ISMETT: Dott.ssa Silvia Riva
Titolo: Randomized, Integrated, Multifactorial, Adaptive Platform Study of Community-Acquired Pneumonia
Acronimo: REMAP-CAP
Disegno dello Studio: studio interventistico, multicentrico, profit, con farmaco
Promotore: University Medical Center Utrecht
Sperimentatore Principale in ISMETT: Dott. Gennaro Martucci
Titolo: Study evaluating the efficacy and safety of Ralinepag in improving treatment outcomes in PAH patients
Acronimo: ROR-PH-301
Disegno dello Studio: studio interventistico, multicentrico, profit, con farmaco
Promotore: United Therapeutics Corporation
Sperimentatore Principale in ISMETT: Dott. Patrizio Vitulo
Titolo: Study evaluating the long-term efficacy and safety of Ralinepag in subjects with IA via an open- label extension
Acronimo: ROR-PH-303
Disegno dello Studio: studio interventistico, multicentrico, profit, con farmaco
Promotore: United Therapeutics Corporation
Sperimentatore Principale in ISMETT: Dott. Patrizio Vitulo
Titolo: A Phase 2b/3, Randomized, Double-Blind, PlaceboControlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)
Acronimo: AV-101-002
Disegno dello Studio: studio interventistico, multicentrico, profit, con farmaco
Promotore: Aerovate Therapeutics
Sperimentatore Principale in ISMETT: Dott. Patrizio Vitulo
Titolo: A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension (PAH)
Acronimo: INS1009-202
Disegno dello Studio: studio interventistico, multicentrico, profit, con farmaco
Promotore: INSMED INCORPORATED
Sperimentatore Principale in ISMETT: Dott. Patrizio Vitulo
Titolo: A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
Acronimo: INS1009-211
Disegno dello Studio: studio Interventistico, multicentrico, profit, con farmaco
Promotore: INSMED INCORPORATED
Sperimentatore Principale in ISMETT: Dott. Patrizio Vitulo
Titolo: Dynamic MULTIcenter project of serious bacterial and fungal infections of the Italian Society of Anti-infective Therapy
Acronimo: MULTI-SITA
Disegno dello Studio: studio osservazionale, multicentrico, no profit, senza farmaco
Promotore: IRCCS San Martino Hospital
Sperimentatore Principale in ISMETT: Dott.ssa Alessandra Mularoni
Titolo: Long-term, multicenter, extension study to evaluate the safety of AV-101 in subjects with pulmonary arterial hypertension (PAH) who completed study AV-101-002
Acronimo: AV-101-003
Disegno dello Studio: studio interventistico, multicentrico, profit, con farmaco
Promotore: Aerovate Therapeutics
Sperimentatore Principale in ISMETT: Dott. Patrizio Vitulo
Titolo: A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease at ISMETT Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione
Acronimo: MK 5475-013
Disegno dello Studio: studio interventistico, multicentrico, profit, con farmaco
Promotore: MSD
Sperimentatore Principale in ISMETT: Dott. Patrizio Vitulo
Titolo: Open-label extension study to evaluate the safety, tolerability and efficacy of long-term use of Treprostinil Palmityl powder for inhalation in participants with pulmonary hypertension associated with interstitial lung disease
Acronimo: INS1009-212
Disegno dello Studio: studio interventistico, multicentrico, profit, con farmaco
Promotore: INSMED INCORPORATED
Sperimentatore Principale in ISMETT: Dott. Patrizio Vitulo
Titolo: Dynamic evaluation of the prognosis of chronic heart failure: MECKI score
Acronimo: MECKI
Disegno dello Studio: studio interventistico, no profit, senza farmaco
Promotore: IRCCS Monzino
Sperimentatore Principale in ISMETT: Dott. Manlio Cipriani
Titolo: Optimal pharmacological therapy in patients with heart failure
Acronimo: OPTIPHARM-HF
Disegno dello Studio: studio osservazionale, multicentrico, no profit, con farmaco
Promotore: ASST degli Spedali Civili di Brescia
Sperimentatore Principale in ISMETT: Dott. Manlio Cipriani
Titolo: A Phase 2b, randomized, controlled, open-label study to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (≥50 years of age) when administered to lung and renal transplant recipients comparing 1 versus 2 doses and compared to healthy controls (≥50 years of age) receiving 1 dose
Acronimo: 2023-503951-81-00
Disegno dello Studio: studio osservazionale, multicentrico, profit, con farmaco
Promotore: GlaxoSmithKline Biologicals S.A
Sperimentatore Principale in ISMETT: Dott.ssa Lavinia Martino
Titolo: Phase 3, randomized, double-blind, placebo-controlled, parallel-group study, followed by open- label extensions, to evaluate the efficacy of oral belumosudil in adult patients with chronic lung allograft dysfunction (CLAD) after bilateral lung transplantation.
Acronimo: EFC17801
Disegno dello Studio: studio osservazionale, multicentrico, profit, con farmaco
Promotore: Sanofi S.r.l.
Sperimentatore Principale in ISMETT: Dott.ssa Lavinia Martino
